Leuprolide

Terazosin as a Non-Hormonal Treatment for Endometriosis.

Int J Mol Sci · 2026

# Summary Research found that terazosin, a non-hormonal medication, reduced multiple inflammatory markers and oxidative stress in endometriotic lesions in a rat model with effectiveness comparable to leuprolide, a standard hormonal treatment. This study demonstrated that terazosin achieved these anti-inflammatory and anti-angiogenic effects without hormonal suppression, suggesting potential as an alternative therapeutic approach that warrants further clinical investigation.

Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP.

J Endocrinol Invest · 2026

# Summary Research found that measuring luteinizing hormone (LH) levels 40 minutes after leuprolide injection provides comparable diagnostic accuracy to the standard GnRH stimulation test for assessing gonadotropic activation in girls with central precocious puberty. This study demonstrated that the post-leuprolide LH measurement could serve as a practical alternative for both initial diagnosis and treatment monitoring in settings where GnRH testing is unavailable.

Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review.

J Pediatr Endocrinol Metab · 2026

Sterile abscesses during GnRH agonist therapy for central precocious puberty: a case series and literature review.

J Pediatr Endocrinol Metab · 2026

Research found that sterile abscesses at injection sites occurred in a small percentage of children receiving long-acting GnRH agonists (including leuprolide) for central precocious puberty, potentially reducing treatment effectiveness. This study demonstrated that topical corticosteroid application may offer a conservative management approach to resolve these abscesses while continuing therapy.

Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study.

Neurourol Urodyn · 2026

Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study.

Neurourol Urodyn · 2026

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Future Oncol · 2026

Research found that in the EMBARK trial, enzalutamide combined with leuprolide demonstrated meaningfully improved efficacy outcomes and overall survival compared with leuprolide alone in patients with high-risk biochemically recurrent prostate cancer. This study demonstrated that the combination treatment maintained quality of life while providing these clinical benefits across various patient subgroups and clinical scenarios.

Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.

Future Oncol · 2026

Research found that in the EMBARK trial, enzalutamide combined with leuprolide demonstrated meaningful improvements in overall survival and other efficacy outcomes compared with leuprolide alone in patients with high-risk biochemically recurrent prostate cancer. This study demonstrated that the combination treatment maintained quality of life while providing clinically relevant benefits across various patient subgroups and definitions of high-risk disease.

Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.

Biomed Chromatogr · 2026

Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study.

Neurourol Urodyn · 2026

Effects of Surgical and Medical Androgen Deprivation on Bladder Remodeling and Steroid Receptor Expression: An Experimental Rat Study.

Neurourol Urodyn · 2026

# Research Summary Research found that different androgen deprivation strategies, including leuprolide acetate, induce significant structural changes in the bladder through alterations in steroid receptor expression and increased cell death pathways. This study demonstrated that leuprolide acetate produced bladder remodeling effects comparable to surgical castration, characterized by tissue atrophy, reduced muscle composition, decreased androgen receptor activity, and increased markers of programmed cell death.

Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS.

Biomed Chromatogr · 2026

Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.

Int Urol Nephrol · 2026

# Summary Research found that leuprolide was associated with interstitial lung disease (ILD) reports, particularly in female patients being treated for breast cancer, as identified through analysis of FDA adverse event reports from 2003–2024. This study demonstrated that among antiandrogen agents analyzed, leuprolide contributed to female-predominant ILD cases, though the signal was not uniquely identified as novel compared to other agents in the drug class.

Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis.

Front Pediatr · 2026

# Research Summary Research found that leuprolide therapy in Taiwanese girls with central precocious puberty enabled approximately half of the treated patients to achieve final adult heights exceeding their genetically predicted mid-parental height, with those starting treatment earlier and showing greater bone age advancement demonstrating the most favorable outcomes. This study demonstrated that while leuprolide therapy supports improved height outcomes in select patients, individualized assessment based on skeletal maturity and growth patterns during treatment is essential for prognostic evaluation.

Add-back estradiol/progesterone to GnRH agonist in PMDD

Am J Obstet Gynecol · 2009

Double-blind crossover RCT (n=27) using leuprolide as an experimental HPA/mood probe in PMDD.

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.

Cancer Chemother Pharmacol · 2026

# Research Summary Research found that a patient with metastatic prostate cancer demonstrated unusual resistance to leuprolide (an LHRH agonist), with testosterone levels failing to decrease and instead progressively rising over five months despite proper administration and adherence. This study demonstrated that switching to an alternative hormonal agent (LHRH antagonist degarelix) successfully achieved testosterone suppression, highlighting the rare possibility of primary LHRH agonist resistance and the importance of monitoring testosterone levels during androgen deprivation therapy.